Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK5 | P34947 | 13/20 | 0.64 |
| ▸ | GRK2 | P25098 | 7/20 | 0.64 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.57 |
| ▸ | MET | P08581 | 7/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18427744 | 0.93 | GRK5 (0.62) | GRK5GRK2MAP4K3FGFR1FGFR2 | |
| SCHEMBL2681319 | 0.91 | FGFR1 (0.57) | GRK5GRK2MAP4K3FGFR1FGFR2 | |
| SCHEMBL2680681 | 0.89 | GRK5 (0.56) | GRK5GRK2MAP4K3FGFR1FGFR2 | |
| SCHEMBL2682031 | 0.88 | GRK5 (0.60) | GRK5GRK2METFLT3KCNH2 | |
| SCHEMBL2682705 | 0.87 | MET (0.66) | GRK5GRK2MAP4K3METFLT3 | |
| SCHEMBL2680979 | 0.86 | GRK5 (0.56) | GRK5GRK2METFLT3KCNH2 | |
| SCHEMBL992230 | 0.86 | MET (0.67) | GRK5GRK2MAP4K3METFLT3 | |
| SCHEMBL18427715 | 0.85 | MET (0.54) | GRK5GRK2MAP4K3FGFR1FGFR2 | |
| SCHEMBL2681889 | 0.85 | MET (0.53) | GRK5GRK2MAP4K3FGFR1FGFR2 | |
| SCHEMBL2680900 | 0.85 | GRK5 (0.61) | GRK5GRK2MAP4K3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | claimed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | claimed |
| EP-2454253-B1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GMBH (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648201-B2 | Aminopyridine derivatives for treating tumors and inflammatory diseases | MERCK PATENT GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115861-A1 | AMINOPYRIDINE DERIVATIVES FOR TREATING TUMORS AND INFLAMMATORY DISEASES | PDK1, PDK2, PDK4 | GRK5 510/4885GRK2 391/4885MAP4K3 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.